Where does MetaCure Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), MetaCure Limited ranks #36,457 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does MetaCure Limited hold?

MetaCure Limited holds 7 US utility patents granted between 2015 and 2017, spanning 8 technology areas.

What is MetaCure Limited's Innovation Score?

MetaCure Limited has an Innovation Score of 32.2 out of 100 (40th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does MetaCure Limited focus on?

MetaCure Limited's top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy) with 6 patents, ranking #583 of 1,943 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is MetaCure Limited's patent grant rate increasing or decreasing?

MetaCure Limited's recent grant velocity is -100% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for MetaCure Limited's patents?

MetaCure Limited's patents average 46.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the MetaCure Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

MetaCure Limited

USPTO PatentsView assignee record - 7 granted patents across 8 technology areas, recorded in grant years 2015–2017. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Metacure ranks #36,457 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 8 technology areas.

#36,457
of 49,997 US assignees by volume: 40th percentile
by Innovation Score (32.2/100): 46.1
avg claims per patent: -100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R36457 · Foreign Corporation #36,457 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 7 grants
MID-PACK #36,457/49,997
PHOTO-FINISH Mercy Medical…
CPC-NARROW A61N · 8 areas
INNOV-THIN 32.2/100
CLAIMS-DENSE 46.1 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -100% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Mercy Medical Research Institute (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Metacure’s 32.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.2 pts (22%) Velocity 0.0 pts (0%) Breadth 10.0 pts (31%) Claim depth 15.0 pts (47%)

Qualcomm Incorporated · highest

85
MetaCure · this assignee

32
3D Lighting… · lowest

7

What this shows Metacure's Innovation Score is 32.2/100 (40th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Metacure?

Each dot is one of Metacure’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Metacure’s own 46.1 claims/patent is ABOVE the 14.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Metacure vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Metacure's grants concentrate

MetaCure Limited is a focused PatentsView assignee: 8 CPC subclasses with 85.7% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2015 (3 grants) versus a trough of 1 in 2017. By volume, Metacure sits between Mercy Medical Research Institute and Mezmeriz, Inc..

Mercy Medical Res…

7
Meril Life Scienc…

7
Meritage Pharma

7
Mesa Digital

7
Metismotion

7
Metronom Health

7
Mettler-toledo Me…

7
Mezmeriz

7
Metacure ◀

7

What this shows MetaCure holds 7 patents at rank #36,500, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near MetaCure

By rank, the assignees closest to #36,500 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in MetaCure's primary technology class.

Metacure's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

32 40th percentile higher than 40% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2017

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

MetaCure Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	3	42.9%
2016	3	42.9%
2017	1	14.3%

Which technologies does MetaCure Limited patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 6

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 2

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 2

A61B - DIAGNOSIS; SURGERY; Identification 2

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 1

G06Q - Information AND Communication Technology [ICT] Specially Adapted FOR Administrative, Commercial, Financial, Managerial OR Supervisory PURPOSES; Systems OR Methods Specially Adapted FOR Administrative, Commercial, Financial, Managerial OR Supervisory Purposes, NOT Otherwise Provided FOR 1

G16Z - Information AND Communication Technology [ICT] Specially Adapted FOR Specific Application Fields, NOT Otherwise Provided FOR 1

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

MetaCure Limited's patent record in context - here's where to go next.

MetaCure Limited's lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 85.7% of its portfolio - see every assignee active in that class. Explore A61N
Ranked #36,457 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare MetaCure Limited against Mercy Medical Research Institute, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 32.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.